News Briefing channel feed

Pro­to­cols: Ed­i­tas adds CRISPR/Cas9 IP; biosim­i­lars make fresh gains in U.S. mar­ket

9 years ago

Pro­to­cols: Trou­bled Teles­ta ax­es staff in wake of FDA re­jec­tion; Evelo part­ners with Mayo re­searchers

9 years ago

Pro­to­cols: Pri­vate eq­ui­ty buy-in val­ues in­Ven­tiv at $3.8B; Cel­gene de­nies char­i­ty scheme al­le­ga­tions

9 years ago

Pro­to­cols: BU’s Out­ter­son helms $350M an­tibi­otics project; Adap­ti­m­mune lands on EMA’s in­side track

9 years ago

Pro­to­cols: Ed­i­tas gets a gene edit­ing col­lab­o­ra­tor; Reg­u­lus hus­tling up re­sponse to clin­i­cal hold; Sanofi drug OK’d

9 years ago

Pro­to­cols: Mer­ck punts ALK al­ler­gy meds; Gene edit­ing gets mixed re­views by a wary pub­lic

9 years ago

Pro­to­cols: Boom­ing Mod­er­na adds staff, new clin­i­cal pro­gram; Lil­ly boasts of R&D gains

9 years ago
First page Previous page 77787980
A service from the Financial Times